TrialBlood2016

Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib.

Shaji K Kumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.